Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
LC–MS strategies for advanced modalities: ADC, AOC, multidomain and RNA therapeutics 4 days 11 hours 2 mins 4 secs REGISTER NOW

Immunogenicity assay development

27 Sep 2018
General interest

Immunogenicity is the patient’s ability to generate antibodies, specific to the ‘dosed protein therapeutic’. In this blog post, Franklin Spriggs (KCAS; KS, USA) explains the importance of antibody-drug antibody assays and how data can be used towards safety profiles.

Click here to read the full blog post.

For more information on KCAS, please click here!


Top content

  • Merck snaps up Terns Pharmaceuticals to expand its oncology pipeline
  • eBook: Precision bioanalysis for every molecule
  • Ask the Experts: quantifying translational biomarkers

Related tags

KCAS
Previous article Next article

Related articles

13 JUN 2018 GENERAL INTEREST
The facts, frustrations and future hopes for immuno-oncology: a podcast with Dr Dominic Warrino (KCAS)
16 APR 2019 GENERAL INTEREST
Tumor microenvironment monitoring: isolation and flow cytometric immunophenotyping of exosomes from human plasma
2 JUL 2018 GENERAL INTEREST
Flow cytometric immunophenotyping of PBMCs and quantification of cytokine production from patients in a peptide vaccine study
2 JUL 2018 GENERAL INTEREST
Why flow cytometry at KCAS? Solving the mysteries of flow cytometry
29 MAY 2018 LARGE MOLECULES
Top 5 techniques and tips for choosing old vs new technologies
4 FEB 2022 NEWS
KCAS to acquire FlowMetric, LLC to better serve cell and gene therapy programs
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone